The kinesin KIF4 mediates HBV/HDV entry through the regulation of surface NTCP localization and can be targeted by RXR agonists in vitro.
Gad SA, Sugiyama M, Tsuge M, Wakae K, Fukano K, Oshima M, Sureau C, Watanabe N, Kato T, Murayama A, Li Y, Shoji I, Shimotohno K, Chayama K, Muramatsu M, Wakita T, Nozaki T, Aly HH.
Gad SA, et al. Among authors: nozaki t.
PLoS Pathog. 2022 Mar 21;18(3):e1009983. doi: 10.1371/journal.ppat.1009983. eCollection 2022 Mar.
PLoS Pathog. 2022.
PMID: 35312737
Free PMC article.